CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Arthur Klausner to participate in the panel "Alternatives for Creating Value in a challenging time" at NASDAQ Healthcare Industry Forum in New York City
News | 12. 08. 2008
